[Cyclosporine A effect in mice C57BL/6 infected with Encephalitozoon intestinalis].
BACKGROUND
Encephalitozoon intestinalis, a parasite belonging to the phylum Microsporidia, is causes gastrointestinal infections in the immunocompromised host. A suitable pharmacologically immunosuppressed animal model for the study of natural E. intestinalis infection, which can establish the immune components that respond to this parasite, is lacking.


OBJECTIVE
To evaluate the effect of immunosuuppression with Cyclosporine A (CsA) in C57BL/ 6 mice on experimental infection with E. intestinalis infection.


METHODS
Eighty C57BL/6 mice were distributed in four treatment groups: Control, CsA-immunosuppressed mice without infection, immunocompetent and immunossuppressed mice infected with E. intestinalis. Mice were immunosuppressed with a weekly dose of 50 mg/Kg body weight of CsA, during the course of the study. Five mice from each group were sacrificed 2, 3, 4 and 6 weeks post-infection, to obtain blood for antibody testing and stool samples were analyzed to assess excretion of spores.


RESULTS
Production of specific IgG antibodies was significantly higher in the immunocompetent group as compared to the immunosuppressed group of experimentally infected mice. In the infected mice, parasites were not observed in any tissues different from the small intestine. However, spore excretion through the stool and duodenal liquid was higher in the group of immunosuppresed infected mice.


CONCLUSIONS
Immunosuppression induced with CsA in the murine model did not allow parasite dissemination and illness progression, but raised kinetics of spore excretion and decreased the production of IgG antibodies.
Galván
Ana Luz
AL
Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia. agalvandiaz@yahoo.com
Agudelo
Sonia del Pilar
Sdel P
Restrepo
Juan Gonzalo
JG
Toro
Fabiola
F
Galviz
Luisa Alejandra
LA
Botero
Jorge
J
D000818:Animals; D016572:Cyclosporine / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D016819:Encephalitozoon / Q000187:drug effects / Q000276:immunology; D016890:Encephalitozoonosis / Q000188:drug therapy*; D005243:Feces / Q000382:microbiology; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D007422:Intestines / Q000382:microbiology / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D011897:Random Allocation
D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D016572:Cyclosporine